Algorae Pharmaceuticals (ASX: 1AI)

The conversations surrounding artificial intelligence (AI) and its scope to transform the pharma industry have been underway for a while now. In fact, reports suggest that the global health-related AI market is set to be worth $284bn by 2030.  Pharmaceutical development company Algorae (ASX: 1AI) is one of the companies at the forefront of this

As of 2023, over 400,000 Australians live with dementia, with over a million people assigned to their care. It is the second leading cause of death in the country overall and the leading cause of death in women. What’s worse, Australia’s growing ageing population makes this statistic all the more worrying.  In a bid to

In a promising new chapter, Algorae Pharmaceuticals (ASX: 1AI), formerly known as Living Cell Technologies (ASX: LCT), has debuted its new name in a Memorandum of Understanding (MoU) with the University of New South Wales (UNSW).  The MoU outlines a framework for a Master Services Research Agreement (MSRA) between both parties to develop an Artificial

As of 2022, Australia is witnessing nearly 400,000 individuals grappling with dementia. Dementia is the second leading cause of death in Australia, and if the trend continues, it might just claim the top spot as the leading cause. But that’s not all – two out of three people with dementia are not hiding away in

Of all the places in the world where you thought a cure for Parkinson’s disease might be found, the remote sub-Antarctic Auckland Islands might not have been your first choice but that’s exactly where biotech company Living Cell Technologies (ASX: LCT) will obtain tissue for their clinical trials.  Specifically, Living Cell Technologies has secured a